<DOC>
	<DOCNO>NCT02930343</DOCNO>
	<brief_summary>RA ( Rheuatoid arthritis ) multisystem disease mainly involve joint result destructive arthritis treat rapidly . Inspite various advance field early diagnosis treatment RA , still need good understand efficacy safety various combination conventional DMARDS , rank order accordingly , give clear vision management RA MTX monotherapy fails , achieve remission soon possible . The study conduct Department Clinical Immunology , JIPMER ( Jawaharlal Institute Postgraduate Medical Education &amp; Research ) . patient fail methotrexate monotherapy randomise 2 treatment arm - either combination Sulfasalazine ( SSZ ) , Hydroxychloroquine ( HCQ ) Methotrexate ( MTX ) Leflunomide ( LEF ) , Hydroxychloroquine ( HCQ ) Methotrexate ( MTX )</brief_summary>
	<brief_title>Comparison Disease Modifying Antirheumatic Drugs Therapy Patients With RA Failing Methotrexate Monotherapy</brief_title>
	<detailed_description>Patients age ≥18 year , fulfil 2010 ACR EULAR criterion RA ( symptom duration less two year ) , 4 joint involve &amp; moderate severe disease activity ( DAS28≥3.2 ) invite participate . After provide write informed consent , eligible patient first start MTX monotherapy &amp; patient persistant moderate disease activity ( DAS28 ESR &gt; 3.2 ) randomize two group . Block randomization do generate random allocation sequence Group 1 - receive MTX+LEF+HCQ Group 2- receive MTX+SSZ+HCQ DMARD dosages use : MTX 25 mg/week orally ( dosage 6 week ) , SSZ 2g/d ( 4 week ) LEF 20 mg/day ( dosage 2 week ) HCQ 200 mg/day . Glucocorticoids give oral taper scheme . All patient prescribe folic acid ( 10 mg/week ) MTX prescription .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Age &gt; 18 year satisfy ACREULAR criterion RA 1 . Polyarthritis ( &gt; 4 joint ) 2 . Disease duration le 2 year 3 . Patients moderate severe disease activity ( DAS28 &gt; 3.2 ) 4 . Patients fail respond initial Methotrexate monotherapy 1 . End stage disease ( deform fix joint ) 2 . Patients vasculitis , extraarticular feature like interstitial lung disease8 3 . Contraindications DMARD therapy ( Chronic Alcoholism , Chronic liver disease , Evidence acute/chronic infection , Chronic kidney disease , Patients leucopenia ( &lt; 3.0×109/l ) , thrombocytopenia ( &lt; 150×109/l ) , AST/ALT &gt; 2× upper normal value creatinine clearance &lt; 30ml/minute ) 4 . Pregnant , lactate woman ; patient ( men woman ) reproductive age group unwilling contraceptive use complete family 5 . Patients unable come regular follow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>